Transgenic Group Inc. (TYO:2342)

Japan · Delayed Price · Currency is JPY

221.00

+7.00 (3.27%)

Aug 6, 2026, 1:04 PM JST

9.41% (1Y)

Market Cap	3.56B +5.9%
Revenue (ttm)	13.17B +1.3%
Net Income	-77.00M
EPS	-4.62
Shares Out	16.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,100
Open	216.00
Previous Close	214.00
Day's Range	216.00 - 221.00
52-Week Range	182.00 - 487.00
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Transgenic Group

Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides analysis of the function of individual genes in individuals, elucidation of the relationship between genes and pathology, production of disease model mice, gene expression analysis, and antibody production; clinical trials for pharmaceutical agents, such as bioequivalence studies; administrative services for clinic... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Employees 227

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 2342

Full Company Profile

Financial Performance

In fiscal year 2026, Transgenic Group's revenue was 13.17 billion, an increase of 1.30% compared to the previous year's 13.01 billion. Losses were -77.00 million, -92.93% less than in 2025.

Financial Statements